Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

G. P. Kaufman, M. A. Gertz, A. Dispenzieri, M. Q. Lacy, F. K. Buadi, D. Dingli, S. R. Hayman, P. Kapoor, J. A. Lust, S. Russell, R. S. Go, Y. L. Hwa, R. A. Kyle, S. V. Rajkumar, S. K. Kumar

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Early high-dose therapy (HDT), consisting of high-dose melphalan and autologous stem cell transplantation following doublet or triplet novel agent induction, is a preferred management strategy for transplant-eligible myeloma patients. We set out to examine the utility of the current fluorescence in situ hybridization (FISH)-based risk stratification in a homogenously treated population of transplant-eligible myeloma patients receiving novel induction regimens and early HDT with or without posttransplant maintenance therapy. FISH was available in 409 patients at the time of diagnosis for patients receiving HDT within 12 months of diagnosis. We present comprehensive outcomes for chromosome 14 translocations and 17p abnormalities that both support and refute current risk stratification models. In contrast to its current classification as a marker of 'standard risk' (SR), t(11;14) was associated with inferior overall survival (OS) when compared with the classical SR cohort. The use of novel agent maintenance therapy (bortezomib or lenalidomide) following early HDT ameliorates the negative prognostic value of high-risk (HR) cytogenetic markers. HR patients who received maintenance following early HDT had similar OS compared with the SR cohort at 5 years.

Original languageEnglish (US)
Pages (from-to)633-639
Number of pages7
Issue number3
StatePublished - Mar 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma'. Together they form a unique fingerprint.

Cite this